Antisense-thioredoxin inhibits angiogenesis via pVHL-mediated hypoxia-inducible factor-1alpha degradation

Woo Jean Kim1, Heeyeong Cho, Sae-Won Lee

  • 1Department of Molecular Biology, Pusan National University, Busan 609-735, Korea.

Insights

Thioredoxin (Trx) promotes tumor angiogenesis by increasing vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1alpha (HIF-1alpha). Antisense Trx inhibits this process by promoting HIF-1alpha degradation, suggesting a therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Thioredoxin (Trx) is overexpressed in many tumors, but its precise function in cancer cells remains unclear.
  • Understanding Trx's role is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To investigate the effect of Thioredoxin (Trx) on tumor cell migration and angiogenesis.
  • To elucidate the relationship between Trx, vascular endothelial growth factor (VEGF), and hypoxia-inducible factor-1alpha (HIF-1alpha) in cancer.

Main Methods:

  • Transfection of Trx or antisense Trx vectors into HT1080 cells.
  • Assessment of endothelial cell migration.
  • Quantification of VEGF and HIF-1alpha protein and RNA levels under normoxic and hypoxic conditions.
  • Analysis of HIF-1alpha translocation and interaction with pVHL.

Main Results:

  • Trx overexpression enhanced endothelial cell migration and increased VEGF and HIF-1alpha levels.
  • Antisense Trx reduced cell migration and decreased HIF-1alpha and VEGF expression.
  • Antisense Trx inhibited HIF-1alpha nuclear translocation and promoted its association with pVHL.

Conclusions:

  • Trx plays a significant role in promoting tumor angiogenesis.
  • Antisense Trx may be a potential therapeutic agent for inhibiting tumor angiogenesis via pVHL-mediated HIF-1alpha degradation.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...